Sign in

You're signed outSign in or to get full access.

RI

ReposiTrak, Inc. (TRAK)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 FY2025 delivered double‑digit growth: revenue rose 16.3% to $5.914M, operating income increased 43% to $1.809M, GAAP net income grew 26.8% to $1.966M, and diluted EPS reached $0.10, all driven by cross‑selling and accelerated traceability onboarding .
  • Results vs S&P Global consensus: EPS beat by $0.01 ($0.10 vs $0.09*), while revenue was modestly below ($5.914M vs $6.000M*, ~1.4% miss); coverage is thin (1 estimate each)*.
  • Management reiterated long‑term targets and confidence: annual revenue growth of 10–20%, rising contribution margin toward 70–80% over fixed costs, and ambition to reach at least 80% gross margin and 30% net margin over time .
  • Capital allocation remains shareholder‑friendly: $28.1M cash, no bank debt; continued preferred redemptions ($0.75M in Q3), quarterly dividend of $0.01815, and buybacks authorized ($7.9M remaining) .
  • Narrative/catalyst: FDA’s 30‑month enforcement delay reduces onboarding risk while adoption remains market‑driven (mandates from major retailers); automation “Wizard” now onboards roughly two‑thirds of traceability customers with little/no human intervention—supporting scalability and margin expansion .

S&P Global disclaimer: Values marked with * were retrieved from S&P Global.

What Went Well and What Went Wrong

What Went Well

  • Broad‑based growth: “We again delivered growth across all business lines - traceability, compliance and supply chain – driven by accelerated cross‑selling,” underpinning 16% revenue growth and 27% GAAP net income growth .
  • Automation scaling: “More than 70% of our new traceability suppliers are now joining the ReposiTrak Traceability Network (RTN) using our automated wizard and with little or no human intervention,” improving onboarding efficiency .
  • Strong operating leverage and cash generation: Operating expenses grew 7% vs 16% revenue; operating income +43%; YTD cash from operations ~$6.76M, supporting dividend and redemptions .
  • Quote: “Fifty cents of every incremental revenue dollar fell to the bottom line… our goal is to deliver $0.70 to $0.80 profit on every dollar of incremental revenue over the annual $12 million in cash costs” .

What Went Wrong

  • Minor revenue shortfall vs consensus: $5.914M actual vs $6.000M estimate (~$0.086M miss, ~1.4%); consensus coverage remains just one estimate, limiting visibility.
  • Deferred revenue stepped down sequentially (still elevated YoY): $3.676M in Q3 vs $4.160M in Q2, reflecting recognition of previously contracted revenue as onboarding accelerated .
  • Cost lines rising with growth investments: Cost of revenue +10% (developer resources for Wizard), sales & marketing +4% (awareness spend), and G&A +8% (benefits/insurance), tempering near‑term margin expansion .

Financial Results

Income Statement Summary

MetricQ3 2024Q2 2025Q3 2025
Revenue ($USD)$5,084,866 $5,490,908 $5,913,732
Operating Income (EBIT, $USD)$1,262,343 $1,352,051 $1,808,853
GAAP Net Income ($USD)$1,550,427 $1,551,080 $1,965,788
Net Income to Common ($USD)$1,416,082 $1,455,464 $1,880,063
Diluted EPS ($USD)$0.08 $0.08 $0.10

Margins (calculated from reported figures)

MetricQ3 2024Q2 2025Q3 2025
EBIT Margin %24.8% (=$1.262M/$5.085M) 24.6% (=$1.352M/$5.491M) 30.6% (=$1.809M/$5.914M)
Net Income Margin %30.5% (=$1.550M/$5.085M) 28.3% (=$1.551M/$5.491M) 33.3% (=$1.966M/$5.914M)

Results vs Consensus

MetricActual Q3 2025Consensus (S&P Global)*Surprise
Revenue ($USD)$5,913,732 $6,000,000*-$86,268 (~-1.4%)*
Primary EPS ($USD)$0.10 $0.09*+$0.01*
# of Estimates (Revenue)—1*—
# of Estimates (EPS)—1*—

S&P Global disclaimer: Values marked with * were retrieved from S&P Global.

KPIs and Liquidity

KPIQ2 2025Q3 2025
Recurring Revenue ($USD)$5.4M $5.8M
Recurring Revenue (% of total)98% 98%
Deferred Revenue ($USD)$4,160,207 $3,675,880
Cash & Equivalents ($USD)$28,041,398 $28,134,321
Cash from Operations YTD ($USD)$5,328,630 $6,763,371
Quarterly Dividend per Share ($USD)$0.01815 $0.01815
Preferred Shares Redeemed (units)70,093 70,093
Common Shares Repurchased (units)4,074 0

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Annual revenue growthMulti‑year10–20% target 10–20% reiterated Maintained
Contribution margin above fixed costMulti‑yearGoal 70–80% Goal 70–80% reiterated Maintained
Gross margin targetMulti‑yearAt least 80% LT target At least 80% LT target reiterated Maintained
Net margin targetMulti‑year~30% LT target ~30% LT target reiterated Maintained
DividendQuarterly$0.01815/share $0.01815/share Maintained
Preferred redemptionMulti‑yearPlan to retire by ~Sep 2027 On pace by ~Sep 2027 Maintained
Capital returnsOngoingReturn ~50% of annual CFO to shareholders Return ~50% reiterated Maintained
OI&E / tax rateFY2025Not provided~$8–9M NOLs remaining; tax rate TBD next call N/A

Earnings Call Themes & Trends

TopicQ1 FY2025 (Sep 2024)Q2 FY2025 (Dec 2024)Q3 FY2025 (Mar 2025)Trend
Traceability adoptionRetailers pushing “trace all foods”; pipeline ~4,000 companies (~5,000 facilities), ~$10M ARR over 18–24 months Accelerating; ~5,500 facilities actively enrolled; ~$10M incremental ARR over ~24 months Pace remains strong despite FDA enforcement delay; downstream suppliers pulled in by upstream customers Strengthening, market‑driven
Automation (Wizard)Process focus; daily tuning; scale via automation rather than headcount Growing % through Wizard; expectation 60–70% no‑assist onboarding ~2/3 of traceability customers onboarding via Wizard with little/no human intervention Rapidly improving
Cross‑sellingCompliance ↔ traceability doorways; 50/50 contribution outside traceability One customer doubling compliance scope; cross‑selling momentum Cross‑selling accelerating across platform Expanding
FDA enforcement timingIndustry likely needs delay; adoption is inevitable Expect delay; adoption driven by competition 30‑month delay confirmed; law unchanged; adoption pace steady Delay reduces risk; adoption persists
Tariffs/macro—Potential transient impact; forward‑buying dynamics Tariff impact minimal; mainly uncertainty; no sales cycle elongation observed Neutral
Capital allocationDividend up; preferred/common redemptions; no bank debt Continue 50% of CFO to shareholders; on pace to retire preferred by ~Sep 2027 Same strategy; $28.1M cash; flexibility to buy common & preferred in same quarter Consistent
New product adjacencies—Recall management; deeper ordering/forecasting (adjacent to traceability) Continued exploration of adjacencies adding high‑margin revenue Pipeline forming
Taxes——~$8–9M NOLs remaining; tax rate update next call NOLs nearing exhaustion

Management Commentary

  • “Revenue grew 16%… operating expenses only grew 7%… operating income 43%… GAAP net income 27%… Fifty cents of every incremental revenue dollar fell to the bottom line” — John Merrill (CFO) .
  • “We are arguably the largest operating traceability network in the world… our common technology platform creates enormous financial and operational efficiencies” — Randy Fields (CEO) .
  • “More than 70% of our new traceability suppliers are now joining… using our automated wizard… with little or no human intervention” — Randy Fields .
  • “Our goal is to return about 50% of our annual cash generation to shareholders… and the other half will go in the bank” — Randy Fields .
  • “We remain confident… will double our historical $20 million annual revenue over the next several years, deliver at least 80% gross margins and 30% net margins” — John Merrill .

Q&A Highlights

  • Tariffs: Management sees minimal impact beyond uncertainty; no evidence of elongated sales cycles in low‑margin food retail .
  • Profit model: Current contribution margin ~50% above fixed costs, targeted to rise to 70–80% as onboarding/marketing spend flattens over 12–20 months .
  • Cross‑selling: Single platform enables deeper relationships and expanding wallet share across compliance, supply chain, and traceability .
  • Capital allocation: Board may execute buybacks and preferred redemptions concurrently depending on opportunity; cumulative capital returns near $25M since inception .
  • Taxes: ~$8–9M of NOLs remaining; management to provide expected tax rate update next call .
  • Product roadmap: Adjacent opportunities (e.g., recall management; deeper ordering/forecasting) expected to carry higher margins on shared platform .

Estimates Context

  • EPS beat: $0.10 actual vs $0.09* consensus (+$0.01); Revenue slight miss: $5.914M actual vs $6.000M (~-1.4%). Coverage is minimal with one estimate for revenue and EPS, which reduces the reliability of “beat/miss” signals relative to larger‑cap peers .
    S&P Global disclaimer: Values marked with * were retrieved from S&P Global.

  • Potential estimate revisions: Given accelerating EBIT margin and strong cash generation, EPS estimates could drift up; however, sequential decline in deferred revenue and elevated onboarding investments may temper near‑term top‑line revisions .

Key Takeaways for Investors

  • ReposiTrak’s growth engine is intact: cross‑selling plus market‑driven traceability adoption is expanding revenue while operating leverage improves; EBIT margin rose ~600 bps QoQ .
  • EPS beat and margin expansion offset a small revenue miss; with only one consensus estimate, focus more on fundamentals and cash conversion than the headline miss* .
  • The FDA enforcement delay reduces implementation risk without slowing adoption—retailers are mandating traceability across all foods, supporting durable pipeline conversion .
  • Automation is a structural advantage: Wizard onboarding at ~two‑thirds of new customers underpins scalable growth and path toward 70–80% incremental contribution margin .
  • Capital return remains robust: dividend maintained, ongoing preferred redemptions, and flexibility to buy back common; $28.1M cash and no bank debt provide optionality .
  • Watch KPIs: recurring revenue ($5.8M) and cash from operations ($6.76M YTD) signal sustainability; monitor deferred revenue levels as a near‑term indicator of upcoming recognition .
  • Medium‑term thesis: As adjacencies (e.g., recall management) roll out on the same platform, mix should tilt to higher‑margin services, supporting the 80% gross/30% net targets .

S&P Global disclaimer: Values marked with * were retrieved from S&P Global.